Allogeneic Cell Therapies Summit Europe

Address Key European Regulatory Challenges and Cutting Edge Platform Design to Advance Allogeneic Approaches

Allogeneic therapies are fast becoming the holy grail for cell therapy as they boast the potential to reduce the cost of goods, improve accessibility, reduce turnaround times and have the ability to treat masses of patients. However, in Europe there are critical challenges limiting clinical advancement, with increased complexities with disharmonized European regulations where guidance varies across countries, and challenges in cross-country logistics when running multicentric trials.

The Allogeneic Cell Therapies Summit Europe is the only industry-focused forum dedicated to address the specific challenges facing European drug developers in order to advance your pipeline to clinical and commercial success.

Collaborate with European leaders from Cellectis, Celyad, GammaDelta Therapeutics, Medicines and Healthcare Products Regulatory Agency and more to benchmark best-in-class approaches to achieve optimal clinical set up and large scale manufacture for your off-the-shelf product. Ensure you have these important considerations planned early in development to overcome delays and critical push backs later in your clinical translation.

Join your community in London this January to take on this next frontier in cell therapy and leave with cutting-edge strategies to develop safe, effective and accessible cell therapies for patients in Europe.

This is your comprehensive guide to define your commercial path forward developing off-the-shelf products.

https://allogeneic-cell-therapies-europe.com/
18-20 January, 2022
London, UK

Contact:
info@hansonwade.com